GLP-1 drugs tied to heart improvements in patients with obesity and heart failure
Everyone in the study had heart failure with reduced ejection fraction, meaning the heart's left ventricle was only weakly pushing blood out toward the body.
The Korean government has announced a crackdown on illegal online sales, brokering, and advertising of GLP-1 obesity drugs, due to rising demand. This crackdown encompasses direct purchases from overseas sellers and secondhand trading of these medications. The Ministry of Food and Drug Safety cautioned that individuals who import such drugs from abroad for personal use, subsequently reselling or distributing them, breach the Pharmaceutical Affairs Act.
As a result, the ministry intends to impose severe penalties on offenders, such as initiating investigations and filing criminal accusations.
On November 12, the government permitted the importation of up to a three-month supply of obesity drugs prescribed overseas. This policy shift has sparked concerns that more buyers will procure cheaper alternatives like Mounjaro and Wegovy abroad to resell domestically. Although prices can vary, a four-week supply of Mounjaro at its lowest dosage costs approximately 300,000 won ($224) in Korea, which is roughly three times the cost of some medical institutions in Japan.
In response to these concerns, the ministry established a reporting center and a task force to closely monitor and investigate any potential violations of the law.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Korea cracks down on illegal online sales of GLP-1 obesity drugs koreatimes.co.kr